Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229675 | 1.00 | KMT2A (0.53) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL31655377 | 1.00 | KMT2A (0.53) | KMT2AMDM4TP53MDM2CASP3 | |
| Hydrochloric Acid SCHEMBL32667324 | 0.99 | KMT2A (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL3309050 | 0.89 | MDM4 (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL31370735 | 0.89 | MDM4 (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL24899366 | 0.89 | MDM4 (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL29423449 | 0.89 | MDM4 (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL2367138 | 0.89 | MDM4 (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL29793991 | 0.89 | MDM4 (0.52) | KMT2AMDM4TP53MDM2CASP3 | |
| SCHEMBL8303670 | 0.89 | MDM4 (0.50) | KMT2AMDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727811-B1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | SHIRE ORPHAN THERAPIES GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-8501787-B2 | Compounds for the inhibition of angiogenesis and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | JERINI AG (DE) | 2007-07-05 | — | — | US | disclosed |
| EP-1727811-A1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | Jerini AG (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090329-A1 | NEW COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND USE OF THEREOF | JERINI AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155712-A1 | Compounds for the inhibition of angiogenesis and use thereof | ITGAV, VCAM1, ITGA5 | KMT2A 2409/4885MDM4 2902/4885TP53 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.